GYRE — Gyre Therapeutics, Inc. Dilution Risk Tracker

Gyre Therapeutics, Inc. (GYRE) has a DilutionScore of 30/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

DilutionWatch tracks 2.1M outstanding warrants for GYRE. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window.

DilutionWatch tracks over 25 SEC filing types for GYRE in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for GYRE alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.